Two other clinical pharmacology studies investigated the relative contributions of slowed gastric emptying, enhanced insulin secretion, glucagon suppression, and splanchnic and peripheral glucose metabolism on postprandial glucose excursions in patients with T2DM after intravenous exenatide administration [75,76]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.